Thomas Grimmsmann1, Wolfgang Himmel2. 1. German Health Insurance Medical Service (MDK) Mecklenburg-Vorpommern, 19059, Schwerin, Germany. t.grimmsmann@mdk-mv.de. 2. Department of General Practice, University of Göttingen, Humboldtallee 38, 37073, Goettingen, Germany.
Abstract
PURPOSE: The aim of this study was to analyse whether the global trend in drug prescriptions for attention-deficit hyperactivity disorders (ADHD), as observed during the last years and often criticized as medicalization, have remained stable or shifted. METHODS: This observational study was based on a secondary analysis of data from a large German database including patients with an ADHD diagnosis between 2008 and 2018. Prescription data comprised all important ADHD drugs. RESULTS: A total of 620 practices delivered data from a total of 77,504 patients (31% of them females) with a diagnosis of AHDH. Nearly 38% (29,396/77,504) of all patients received, at least, one prescription for an ADHS medicine between 2008 and 2018. The number of patients receiving a drug steadily increased annually until 2012 and then slowly fell, but unevenly distributed across the age groups. While the number of younger patients ( ≤ 16 years) receiving a prescription fell by 24% and the defined daily doses (DDDs) remained stable, the number of patients between 17 and 24 years receiving a prescription increased by 113% and the DDDs by 150%. Respectively, the number of older adults (≥ 25 years) with a prescription increased by 355% and the DDDs by 515%. Nearly one-third of older adults received an ADHD medicine only once. CONCLUSION: The ever-increasing prescription of ADHD medicines stopped some years ago for children. ADHS and its pharmacological management are increasingly observed among older adolescents and adults, with a different pattern of drug persistence compared with children.
PURPOSE: The aim of this study was to analyse whether the global trend in drug prescriptions for attention-deficit hyperactivity disorders (ADHD), as observed during the last years and often criticized as medicalization, have remained stable or shifted. METHODS: This observational study was based on a secondary analysis of data from a large German database including patients with an ADHD diagnosis between 2008 and 2018. Prescription data comprised all important ADHD drugs. RESULTS: A total of 620 practices delivered data from a total of 77,504 patients (31% of them females) with a diagnosis of AHDH. Nearly 38% (29,396/77,504) of all patients received, at least, one prescription for an ADHS medicine between 2008 and 2018. The number of patients receiving a drug steadily increased annually until 2012 and then slowly fell, but unevenly distributed across the age groups. While the number of younger patients ( ≤ 16 years) receiving a prescription fell by 24% and the defined daily doses (DDDs) remained stable, the number of patients between 17 and 24 years receiving a prescription increased by 113% and the DDDs by 150%. Respectively, the number of older adults (≥ 25 years) with a prescription increased by 355% and the DDDs by 515%. Nearly one-third of older adults received an ADHD medicine only once. CONCLUSION: The ever-increasing prescription of ADHD medicines stopped some years ago for children. ADHS and its pharmacological management are increasingly observed among older adolescents and adults, with a different pattern of drug persistence compared with children.
Entities:
Keywords:
Ambulatory care; Attention-deficit disorder with hyperactivity; Cohort studies; Drug prescriptions; Methylphenidate
Authors: Christian J Bachmann; Linda P Wijlaars; Luuk J Kalverdijk; Mehmet Burcu; Gerd Glaeske; Catharina C M Schuiling-Veninga; Falk Hoffmann; Lise Aagaard; Julie M Zito Journal: Eur Neuropsychopharmacol Date: 2017-03-20 Impact factor: 4.600
Authors: J J S Kooij; D Bijlenga; L Salerno; R Jaeschke; I Bitter; J Balázs; J Thome; G Dom; S Kasper; C Nunes Filipe; S Stes; P Mohr; S Leppämäki; M Casas; J Bobes; J M Mccarthy; V Richarte; A Kjems Philipsen; A Pehlivanidis; A Niemela; B Styr; B Semerci; B Bolea-Alamanac; D Edvinsson; D Baeyens; D Wynchank; E Sobanski; A Philipsen; F McNicholas; H Caci; I Mihailescu; I Manor; I Dobrescu; T Saito; J Krause; J Fayyad; J A Ramos-Quiroga; K Foeken; F Rad; M Adamou; M Ohlmeier; M Fitzgerald; M Gill; M Lensing; N Motavalli Mukaddes; P Brudkiewicz; P Gustafsson; P Tani; P Oswald; P J Carpentier; P De Rossi; R Delorme; S Markovska Simoska; S Pallanti; S Young; S Bejerot; T Lehtonen; J Kustow; U Müller-Sedgwick; T Hirvikoski; V Pironti; Y Ginsberg; Z Félegyházy; M P Garcia-Portilla; P Asherson Journal: Eur Psychiatry Date: 2018-11-16 Impact factor: 5.361
Authors: Barbara Franke; Giorgia Michelini; Philip Asherson; Tobias Banaschewski; Andrea Bilbow; Jan K Buitelaar; Bru Cormand; Stephen V Faraone; Ylva Ginsberg; Jan Haavik; Jonna Kuntsi; Henrik Larsson; Klaus-Peter Lesch; J Antoni Ramos-Quiroga; János M Réthelyi; Marta Ribases; Andreas Reif Journal: Eur Neuropsychopharmacol Date: 2018-09-06 Impact factor: 4.600